Centrient Accuses India’s Dalas Of Amoxicillin Patent Infringement

Centrient Pharmaceuticals, which makes “sustainable antibiotics,” has filed an Indian lawsuit in the Delhi High Court against Dalas Biotech accusing the Indian company of patent infringement over its amoxicillin trihydrate API.

Amoxicillin
Centrient’s Lawsuit Revolves Around An Amoxicillin Process Patent • Source: Shutterstock

Centrient Pharmaceuticals, which seeks to use “green technology” to make generic antibiotics and other drugs, has slapped Dalas Biotech with a lawsuit accusing the Indian company of patent infringement involving its amoxicillin trihydrate API.

In its lawsuit filed in the Delhi High Court, Centrient’s Indian subsidiary, Centrient Pharmaceuticals Private Ltd., asked for a permanent...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Legal & IP

  • ADHD

    This is regarding ADHD.

  • GB-Leadership-Free: Article with 150 words (Time to read is < 1 min)

     
    • By 

    In the first cinematic chapter of J.K. Rowling’s wizarding world, young Harry Potter discovers his true identity and enters Hogwarts School of Witchcraft and Wizardry. This enchanting origin story sets the tone for a saga filled with magic, loyalty, and the power of choice.

  • MPP Finds Three More Partners On Key Hepatitis C Treatment

     
    • By 

    The Medicines Patent Pool has entered into a partnership with three companies for glecaprevir/pibrentasvir, a WHO-recommended treatment for people living with hepatitis C. The companies join previous generic licensee Mylan and originator AbbVie.

  • Troubled Teligent Enters Bankruptcy Proceedings As CEO Resigns

     
    • By 

    Teligent is pursuing an asset sale process to “maximize the value of the company” after entering into Chapter 11 bankruptcy proceedings in the US. The firm – which has also seen CEO Tim Sawyer resign – had been struggling of late with remediation issues to address a warning letter at its Buena manufacturing facility in New Jersey, as well as a recent recall.

More from Generics Bulletin